Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$0.35 - $0.56 $44,315 - $70,904
-126,615 Reduced 57.48%
93,676 $38,000
Q1 2023

May 15, 2023

SELL
$0.36 - $0.63 $38,003 - $66,505
-105,565 Reduced 32.4%
220,291 $82,000
Q4 2022

Feb 14, 2023

SELL
$0.41 - $18.6 $22,361 - $1.01 Million
-54,540 Reduced 14.34%
325,856 $156,000
Q3 2022

Nov 14, 2022

SELL
$0.57 - $34.65 $687,237 - $41.8 Million
-1,205,679 Reduced 76.02%
380,396 $327,000
Q2 2022

Aug 15, 2022

BUY
$0.85 - $1.41 $1.35 Million - $2.24 Million
1,586,075 New
1,586,075 $1.48 Million
Q1 2022

May 16, 2022

SELL
$1.16 - $2.5 $421,997 - $909,477
-363,791 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.46 - $8.74 $810,498 - $2.88 Million
329,471 Added 960.0%
363,791 $895,000
Q3 2021

Nov 15, 2021

BUY
$5.1 - $9.39 $175,032 - $322,264
34,320 New
34,320 $293,000
Q2 2021

Aug 16, 2021

SELL
$3.95 - $6.88 $1.52 Million - $2.65 Million
-385,860 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$2.01 - $5.55 $775,578 - $2.14 Million
385,860 New
385,860 $1.71 Million
Q4 2018

Feb 14, 2019

SELL
$0.92 - $1.31 $22,581 - $32,153
-24,545 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$1.11 - $1.64 $27,244 - $40,253
24,545 New
24,545 $32,000
Q1 2018

May 15, 2018

SELL
$1.51 - $3.21 $31,235 - $66,402
-20,686 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$2.18 - $5.7 $42,335 - $110,694
-19,420 Reduced 48.42%
20,686 $47,000
Q3 2017

Nov 14, 2017

BUY
$2.84 - $8.59 $113,901 - $344,510
40,106
40,106 $218,000

Others Institutions Holding PAVM

# of Institutions
1
Shares Held
2.24M
Call Options Held
0
Put Options Held
0

About PAVmed Inc.


  • Ticker PAVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 90,999,104
  • Market Cap $93.7M
  • Description
  • PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted ne...
More about PAVM
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.